CN100365007C - New type trisaccharide and penta saccharid oligo saccharide antigen, their synthesis method and application in preparation of medicine for inhibiting exclusion reaction - Google Patents
New type trisaccharide and penta saccharid oligo saccharide antigen, their synthesis method and application in preparation of medicine for inhibiting exclusion reaction Download PDFInfo
- Publication number
- CN100365007C CN100365007C CNB031560989A CN03156098A CN100365007C CN 100365007 C CN100365007 C CN 100365007C CN B031560989 A CNB031560989 A CN B031560989A CN 03156098 A CN03156098 A CN 03156098A CN 100365007 C CN100365007 C CN 100365007C
- Authority
- CN
- China
- Prior art keywords
- compound
- obtains
- reaction
- deprotection
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
The present invention relates to trisaccharide and pentasaccharide oligose antigens disclosed in the general formula I, the general formula II and the general formula III, a method for synthesizing the trisaccharide and pentasaccharide oligose antigens disclosed in the general formula I, the general formula II and the general formula III by utilizing the method of synthesis in a single reactor, and the application of the trisaccharide and pentasaccharide oligose antigens to preparing a medicine for inhibiting the rejection reaction in organ heterotransplantation.
Description
Invention field
The present invention relates to novel trisaccharide and pentasaccharides oligosaccharides antigen, their " a still synthesis method " synthetic method, and their purposes in the medicine of the rejection of preparation inhibition xenotransplant.
Background technology
Xenotransplant is considered to solve one of method of donor organ shortage in the organ transplantation.Super immunological rejection is regarded as the challenging obstacle of tool in the xenotransplant.It is gone up the pulsating antigen of Gal 1 → 3Gal-R oligosaccharides that contains of expressing by the non-primate organ cell of the natural antibody specific recognition of a kind of anti-Gal by name in the human recycle system and is caused.In coming with synthetic oligosaccharides antigen and anti-Gal antibody be one of possible approach that suppresses super immunological rejection.We have successfully made up the oligosaccharides antigen series relevant with xenotransplant with the method for " still is synthetic ".
Relevant studies show that, trisaccharide Gal 1-3Gal 1-4Glc-R (1), Gal 1-3Gal 1-4Glc NAc-R (2) and pentasaccharides Gal 1-3Gal 1-4GlcNAc 1-3Gal 1-4Glc-R (3) are that the main ingredient of Gal epitope (is consulted (a) Cooper, D.K.C.; Koren, E.; Oriol, R.Immunol.Rev.1994,141,31. (b) Galili, U.Immunol.Today 1993,14,480. (c) Sandrin, M.S.; Vaughan, H.A.; McKenzie, I.F.C.Transplant.Rev.1994,8,134. (d) Samuelsson, B.E.; Rydberg, L.; Breimer, M.E.; Backer, A.; Gustavsson, M.; Holgersson, J.; Karlsson, E.; Uyterwaal, A.-C.; Cairns, T.; Welsh, K.Immunol.Rev.1994,141,151).(consult Zhu, T. though there is bibliographical information it to be synthesized to have carried out studying with the method for chemistry and enzyme; Boons, G.-J.J.Chem.Soc., Perkin Trans.1 1998,857; Gege, C.; Kinzy, W.; Schmi dt, R.R.Carbohydr.Res.2000,328,459; And Fang, J.; Li, J.; Chen, X.; Zhang, Y.; Wang, J.; Guo, Z.; Zhang, W.; Yu, L.; Brew, K.; Wang, P.G.J.Am.Chem.Soc.1998,120,6635.), but the synthetic step is more, and total recovery is low, the requirement of the relatively large oligosaccharides sample of can not satisfying the demand.The protecting group that we here select to use always is carried out suitable protection to sugared construction module, then these construction modules is assembled with " a still synthesis method ", has obtained three required novel oligosaccharides antigen series expeditiously.
Summary of the invention
Therefore, the purpose of this invention is to provide three sugar compounds of formula I and II, the pentasaccharides compound of formula III, or their pharmaceutical salts or solvated compounds:
R wherein
1-R
2And R
5-R
6Be that hydrogen or protecting group are (as Bn, or R
1And R
2, or R
5And R
6Be the benzal base together); R
3-R
4And R
8-R
11Be hydrogen or protecting group (as Bn); R
7Be H or protecting group (as acyl group, benzoyl for example, ethanoyl, chloracetyl, propionyl, valeryl); R
12Be H or protecting group (as Cbz).
R wherein
13-R
14And R
17-R
18Be that hydrogen or protecting group are (as Bn, or R
13And R
14, or R
17And R
18Be the benzal base together); R
15-R
16And R
20-R
21Be hydrogen or protecting group (as Bn); R
19Be H or protecting group (as acyl group, benzoyl for example, ethanoyl, chloracetyl, propionyl, valeryl); R
23Be hydrogen or protecting group (as Cbz); R
22Be hydrogen or protecting group (for example-NR
22Be-NH
2,-N
3, phthalimide-based ,-NHC (O) O-CH
2CCl
3,-NHAc etc.).
R wherein
24-R
25, R
28-R
29And R
34-R
35Be that hydrogen or protecting group are (as Bn, or R
24And R
25, or R
28And R
29, or R
34And R
35Be the benzal base together); R
26-R
27And R
31-R
32, R
36-R
40Be hydrogen or protecting group (as Bn); R
30Be hydrogen or protecting group (as acyl group, benzoyl for example, ethanoyl, chloracetyl, propionyl, valeryl); R
33Be hydrogen or protecting group (NR
33For example be-NH
2,-N
3, phthalimide-based ,-NHC (O) O-CH
2CCl
3,-NHAc etc.); R
41Be hydrogen or protecting group (for example Cbz).
The preparation method of the compound of formula I of the present invention comprises:
(A) allow 1,2,3,4,6-penta-acetyl glucose:
In the presence of etherate of trifluoroboron and inert solvent (as aprotic solvent) with HO (CH
2)
3The NHCbz reaction to introduce side chain, obtains compound 5:
(B) deacetylation is followed the protection of benzal base then, obtains compound 6:
(C) benzylization then obtains compound 7:
(D) selective opening then obtains compound 8:
(E) compound 8 and following compound 9 and 10 couplings then,
Acquisition formula 1 compound, optional deprotection:
The preparation method of the compound of formula II may further comprise the steps:
(A) with compound 11
With HO (CH
2)
3The NHCbz reaction to introduce side chain, obtains compound 12:
(B) selective opening then obtains compound 13:
(C) compound 13 and above compound 9 and 10 couplings then obtain compound 2, optional deprotection:
The preparation method of the compound of formula 3 comprises:
(A), obtain compound 14 with above compound 9 and 10 couplings:
(B) with lactose 15:
Acetylize obtains compound 16:
Then with HO (CH
2)
3The NHCbz reaction to introduce side chain, obtains compound 17:
Deacetylated then, introduce allyl group, benzylization obtains compound 18:
Take off allyl group then, obtain compound 19:
(C) compound 14, compound 19 and following compound 20 couplings,
Obtain compound 3, optional again deprotection:
Compound 1,2 and 3 synthetic route are as follows respectively.
The synthetic route of trisaccharide 1:
The synthetic route of trisaccharide 2:
The synthetic route of pentasaccharides 3:
The condition that forms the linked reaction of oligosaccharides comprises: activator is selected from: NIS/TfOH, DMTST, BSP/Tf
2O, PhSCl/AgOTf etc.; Temperature :-78 ℃ to room temperature; Reaction solvent is selected from: toluene, methylene dichloride, chloroform, acetonitrile, DMF, THF, DME etc.
Compound 1 can be successively with 1) NaOMe/MeOH and 2) H
2/ Pd-C/H
2O/THF/CH
3COOH handles deprotection, obtains the compound 1a of following formula:
Compound 2 can be successively with the alcoholic solution of methylamine (room temperature to 60 ℃), 2) Ac
2O/Pyr, 3) NaOMe/MeOH and 4) H
2/ Pd-C/THF/H
2O/CH
3COOH handles deprotection, obtains following formula: compound 2a:
Compound 3 can be successively with 1) alcoholic solution of methylamine (room temperature to 60 ℃), 2) Ac
2O/Pyr, 3) NaOMe/MeOH and 4) H
2/ Pd-C handles deprotection, obtains following formula: compound 3a:
Another object of the present invention provides the purposes that above-claimed cpd or pharmaceutical salts or solvate are used to prepare the immunosuppressive drug that anti-xenotransplant repels.
Another purpose of the present invention provides the above-claimed cpd that contains significant quantity or the pharmaceutical composition of pharmaceutical salts or solvate.Compound of the present invention can also contain pharmaceutically acceptable carrier (as injection or transfusion physiological saline).
Compound of the present invention can use separately, and form that also can composition is used.Compound of the present invention preferably uses with the form of injection or infusion preparation.Usually, the dosage of The compounds of this invention will be in the scope of 0.1mg/kg/d to 10mg/kg/d body weight.
Embodiment
Come by the following examples further to set forth the present invention, it should be understood that these embodiment only are used for the purpose of illustration, do not constitute limitation of the scope of the invention.
The synthesis step of embodiment 1, trisaccharide 1:
(1) compound 5 is synthetic
1,2,3,4, (7g is 0.018mol) with compound H O (CH for 6-penta-acetyl glucose
2)
3NHCbz (Zhu, T.; Boons, G.-J.Angew.Chem.In t.Ed.1999,38,3495.) (4.49g 0.0216mol) in the 250ml eggplant-shape bottle, adds the dry CH of 100ml
2Cl
2BF is injected in dissolving
3.OEt
2(15.3ml, 15.32g 0.108mol), stir 8h under the room temperature, and stopped reaction adds 100ml CH
2Cl
2Saturated NaHCO is used in dilution successively
3With the NaCl washing, anhydrous sodium sulfate drying filters, and concentrates, and gets yellow oil, and resistates uses column chromatography [eluent sherwood oil: ethyl acetate (V/V)=1: 1] and gets yellow syrup 3.94g, yield: 40%.
1HNMR (300MHz, CDCl
3) δ: 7.20-7.29 (m, 5H), 5.15-5.20 (m, 1H), 5.10 (t, J=9.6Hz, 1H), 4.91-5.02 (m, 3H), 4.87 (dd, J=8.1,9.3Hz, 1H), 4.40 (d, J=7.8Hz, 1H), 4.14 (dd, J=4.5,12.3Hz, 1H), 4.03 (dd, J=2.4,12.0Hz, 1H), 3.80 (dt, J=9.9,5.4Hz, 1H), 3.56-3.60 (m, 1H), 3.48 (dt, J=9.3,4.4Hz, 1H), 3.0.-3.24 (m, 2H), 1.97 (s, 3H), 1.94 (s, 3H), 1.92 (s, 3H), 1.89 (s, 3H), 1.67-1.70 (m, 2H);
13CNMR (75MHz, CDCl
3) δ: 170.46,170.00,169.20,156.26,136.45,128.25,127.85,127.82,100.36,72.49,71.54,70.96,68.10,67.27,66.25,61.60,37.86,29.23,20.45,20.37,20.35; FAB-MS (M+H
+) 540. ultimate analyses (%): C
25H
33O
12N calculated value: C:55.65, H:6.16, N:2.60. measured value: C:55.80, H:6.19, N:2.30.
(2) compound 6 is synthetic
Compound 5 (2.97g, 5.51mmol) in the 150m1 reaction flask, add the dissolving of 50ml anhydrous methanol, inject NaOMe (0.2ml, 30% methanol solution, 0.55mmol), stirring at room 5h, stopped reaction adds strongly acidic cation-exchange and is neutralized to neutrality, behind the elimination resin, concentrate drain yellow oil.In reaction flask, add anhydrous acetonitrile (60ml) again, add benzaldehyde dimethyl acetal (1.0ml, 1.00g, 6.61mmol) and camphorsulfonic acid (0.11g, 0.44mmo1), behind the stirring at room 5min, the adularescent solid is separated out, restir 5h, solution becomes clarification, and the TLC detection reaction is intact, add the triethylamine neutralization, concentrate solvent evaporated, resistates uses column chromatography [eluent sherwood oil: ethyl acetate (V/V)=1: 1] and gets white crystal 1.67g, yield: 66.0%.
1HNMR (500MHz, DMSO-d
6) δ: 7.24-7.45 (m, 10H), 5.57 (s, 1H), 5.29 (dd, J=5.0,13.5Hz, 1H), 5.01 (m, 2H), 4.32 (d, J=8.0Hz, 1H), 4.17 (dd, J=3.5,10.0Hz, 1H), 3.73 (dt, J=10.0,5.0Hz, 1H), 3.66-3.70 (m, 1H), 3.49 (dt, J=9.0,4.5Hz, 1H), 3.163.20 (m, 6H), and 3.09-3.06 (m, 2H), 1.70-1.65 (m, 2H);
13CNMR (125MHz, DMSO-d
6) δ: 156.13,137.78,137.25,128.83,128.37,128.03,127.78,126.33,103.44,100.63,80.60,74.31,72.85,67.95,66.83,65.77,65.15,37.48,29.65; FAB-MS (M+H
+) 460. ultimate analyses (%): C
24H
29O
8N calculated value: C:62.73, H:6.36, N:3.05. measured value: C:62.55, H:6.38, N:2.83.
(3) compound 7 is synthetic
Compound 6 (1.62g, 3.53mmol) join in the 150ml eggplant-shape bottle, inject DMF (30ml) dissolving, be cooled to 0 ℃, and adding NaH (0.36g, 14.12mmol), inject BnBr (1.71ml, 2.41g 14.12mmol), the stirring at room reaction is spent the night, stopped reaction, compound is poured in the frozen water, used ethyl acetate (3 * 30ml) extractions, ethyl acetate layer anhydrous sodium sulfate drying then, filter, concentrate, resistates uses column chromatography [eluent sherwood oil: ethyl acetate (V/V)=4: 1] and gets yellow syrup 2.5g, yield: 97%.
1HNMR (500MHz, DMSO-d
6) δ: 7.21-7.43 (m, 25H), 5.66 (s, 1H), 5.10 (br.s, 2H), 4.45-4.78 (m, 7H), 4.20 (m, 1H), 4.10 (q, J=5.0Hz, 1H), 3.68-3.76 (m, 4H), 3.38-3.54 (m, 2H), 3.28 (m, 2H), 1.76 (m, 2H);
13CNMR (125MHz, DMSO-d
6) δ: 155.79,138.67,138.42,138.12,137.60,136.93,128.74,128.46,128.35,128.05,127.77,127.53,127.45,127.39,127.34,127.11,126.95,125.93,102.88,100.05,81.65,80.52,80.13,74.05,73.67,67.82,67.00,66.86,66.35,65.18,49.99,28.35.FAB-MS (M+H
+) 730. ultimate analyses (%): C
45H
47O
8N calculated value: C:74.05, H:6.49, N:1.92. measured value: C:73.91, H:6.49, N:1.76.
(4) compound 8 is synthetic
(2.4g, 3.29mmol), 3 MS (2.5g) inject dry THF (50ml) N to add compound 7 in reaction flask
2Protection, stirring at room 0.5h adds NaCNBH
3(2.7g 0.041mol), injects HCl-Et
2(66ml, the diethyl ether solution of 1M 65.8mmol), have bubble to emit to O, and the 10min afterreaction is intact, add 60ml methylene dichloride stopped reaction, and diatomite filtration removes 3 MS, and filtrate is used saturated NaHCO successively
3With the NaCl washing, anhydrous sodium sulfate drying filters, and concentrates, and gets yellow oil, and column chromatography for separation [eluent sherwood oil: ethyl acetate (V/V)=3: 1] gets yellow syrup 2.11g, yield: 88%.
1HNMR (300MHz, DMSO-d
6) δ: 7.23-7.32 (m, 25H), 5.40 (d, J=6.0Hz, 1H), 5.09 (br.s, 2H), 4.364.82 (m, 10H), 4.074.12 (m, 2H), 3.71-3.75 (m, 2H), 3.29-3.55 (m, 4H), 1.78 (m, 2H);
13CNMR (75MHz, CDCl
3) δ: 156.59,138.50,138.26,137.79,137.74,136.64,129.65,128.89,128.45,128.42,128.37,128.31,128.25,127.91,127.85,127.76,127.71,127.62,127.57,127.22,103.45,83.90,81.58,76.21,75.16,74.59,73.98,73.53,71.36,70.07,67.13,58.20,50.63,28.56; FAB-MS (M+H
+) 732. ultimate analyses (%): C
45H
49O
8N calculated value: C:73.85, H:6.75, N:1.91. measured value: C:74.12, H:6.87, N:1.72.
(5) trisaccharide 1 is synthetic
Add 4 MS (500mg) in the 50ml reaction flask, compound 9 (is consulted Zhang, Z.; Ollmann, I.R.; Ye, X.-S.; Wischnat, R.; Baasov, T.; Wong, C.-H.J.Am.Chem.Soc.1999,121,734.) (163mg, 0.25mmol), compound 10 (is consulted Zhang, Z.; 0llmann, I.R.; Ye, X.-S.; Wischnat, R.; Baasov, T.; Wong, C.-H.J.Am.Chem.Soc.1999,121,734.) (100mg, 0.209mmol), dry CH is injected in nitrogen protection
2Cl
2(10ml) stir 0.5h, add NIS (132.3mg under the frozen water condition, 0.25mmol), TfOH (42 μ l, 0.5M diethyl ether solution, 0.021mmol), TLC[sherwood oil behind the reaction 0.5h: acetone (v/v)=3: 2] show that raw material 10 primitive reactions are intact and generate a new point, add compound 8 (229mg again, 0.313mmol), NIS (132.3mg, 0.25mmol), TfOH (42 μ l, 0.5M diethyl ether solution, 0.021mmol), TLC[sherwood oil behind the reaction 3h: acetone (v/v)=3: 2] detect to show that the new point that previous step generates disappears substantially, adds triethylamine (2ml) and CH
2Cl
2(15ml) dilution, diatomite filtration removes 4 MS, and filtrate is used saturated NaHCO successively
3With the NaCl washing, anhydrous sodium sulfate drying filters, and concentrates, and resistates uses column chromatography [eluent sherwood oil: acetone (v/v)=4: 1] and gets yellow oil 175mg, yield 55%.
1HNMR (500MHz, DMSO-d
6) δ: 7.94 (d, J=7.5Hz, 2H), 7.61 (t, J=7.5Hz, 1H), 7.10-7.41 (m, 52H), 5.54 (s, 1H), 5.34 (dd, J=8.5,10.0Hz, 1H), 5.29 (d, J=3.0Hz, 1H), 5.06 (br.s, 3H), 4.82 (d, J=7.5Hz, 1H), 4.18-4.72 (m, 17H), 3.93-4.03 (m, 3H), 3.72-3.79 (m, 4H), 3.40-3.50 (m, 6H), and 3.16-3.28 (m, 7H), 1.66-1.82 (m, 2H);
13CNMR (125MHz, DMSO-d
6) δ: 164.49,139.13,138.56,138.49,138.25,138.11,136.89,133.56,129.35,128.97,128.69,128.41,128.27,128.23,128.17,128.06,128.00,127.84,127.72,127.54,127.46,127.36,127.29,127.12,126.96,126.17,102.01,100.33,99.85,93.10,82.13,81.15,77.69,77.21,75.06,74.38,74.17,73.99,73.56,73.43,73.33,72.41,72.09,71.87,71.13,70.74,68.92,68.21,68.10,66.27,66.23,49.92,43.63,38.99,29.00; MALDI-TOF-MS (M+Na
+) 1630, (M+K
+) 1646. ultimate analyses (%): C
99H
101O
19N calculated value: C:73.91, H:6.33, N:0.88. measured value: C:73.66, H:6.53, N:0.56.
(6) deprotection of trisaccharide 1
In the 50ml reaction flask, add trisaccharide 1 (50mg), methyl alcohol (15ml), sodium methylate (0.1ml, 30% methanol solution), stirring at room 6h adds strongly acidic cation-exchange and is neutralized to neutrality, and behind the elimination resin, filtrate concentrates evaporate to dryness.Residue is dissolved in 4mlHOAc: H
2O: THF=4: in 2: 1 the solvent, add 10%Pd/C (10mg), in the High Purity Hydrogen producer, carry out hydrogenation, after having reacted, filter out Pd/C, fully wash with methyl alcohol.With C-18 reverse phase silica gel column purification, get the pure product of compound 1a, productive rate 92%.
The synthesis step of embodiment 2, trisaccharide 2:
(1) compound 12 is synthetic
Add 4 MS (400mg) in the 50ml reaction flask, compound 11 (is consulted Koeller, K.M.; Wong, C.-H.Chem.Rev.2000,100,4465.) (100mg, 0.18mmol), compound H O (CH
2)
3(48.6mg, 0.22mmol), dry CH is injected in nitrogen protection to NHCbz
2Cl
2(10ml) stir 0.5h, (39.5mg, 0.18mmol), (0.034mmol), the 2h afterreaction is intact for 69 μ l, the diethyl ether solution of 0.5M, adds triethylamine (1ml) neutralization, adds CH for TfOH to add NIS under the frozen water condition
2Cl
2(15ml) dilution, diatomite filtration removes 4 MS, and filtrate is used saturated NaHCO successively
3With the NaCl washing, anhydrous sodium sulfate drying filters, and concentrates, and resistates uses column chromatography [eluent sherwood oil: ethyl acetate (V/V)=1: 1] and gets faint yellow solid 56mg, yield 49%.
1HNMR (500MHz, DMSO-d
6) δ: 7.717.92 (m, 4H), 7.49 (d, J=6.5Hz, 2H), 7.26-7.49 (m, 7H), 7.07 (t, J=5.0Hz, 1H), 6.97 (t, J=7.0Hz, 1H), 6.87-6.92 (m, 4H), 5.77 (s, 1H), 5.14 (d, J=8.5Hz, 1H), 4.85 (br.s, 2H), 4.70 (d, J=12.0Hz, 1H), 4.40 (d, J=12.5Hz, 1H), 4.28-4.32 (m, 2H), 3.99 (dd, J=8.5,10.5Hz, 1H), 3.98 (t, J=9.5Hz, 1H), 3.85 (t, J=10.0Hz, 1H), 3.67 (t, J=10.0Hz, 1H), 3.58 (dt, J=4.5,9.0Hz, 1H), 3.343.42 (m, 2H), 3.16 (m, 1H), 2.76-2.80 (m, 2H), 1.40-1.49 (m, 2H);
13CNMR (125MHz, DMSO-d
6) δ: 167.42,155.87,137.77,137.55,137.18,134.72,130.74,128.88,128.32,128.21,127.91,127.74,127.53,127.37,126.03,123.38,100.24,98.30,81.87,74.57,73.14,67.75,66.70,65.71,65.04,55.38,36.84,29.41; FAB-MS (M+H
+) 679. ultimate analyses (%): C
39H
38O
9N
2Calculated value: C:69.01, H:5.64, N:4.13. measured value: C:68.95, H:5.64, N:3.92.
(2) compound 13 is synthetic
(440mg, 0.66mmol), 3 MS (2.5g) inject dry THF (50ml), N to add compound 12 in reaction flask
2Protection, stirring at room 0.5h adds NaCNBH
3(546mg 8.25mmol), injects HCl-Et
2(13.2ml, the diethyl ether solution of 1M 13.2mmol), have bubble to emit to O, and the 30min afterreaction is intact, add 50ml methylene dichloride dilute reaction solution, and diatomite filtration removes 3 MS, and filtrate is used saturated NaHCO successively
3With the NaCl washing, anhydrous sodium sulfate drying filters, and concentrates, and gets yellow oil, and column chromatography for separation [eluent sherwood oil: ethyl acetate (V/V)=1: 1] gets yellow syrup 400mg, yield: 91%.
1HNMR (300MHz, DMSO-d
6) δ: 7.73-7.85 (m, 4H), 7.28-7.37 (m, 9H), 7.07 (t, J=5.7Hz, 1H), 6.86-6.94 (m, 5H), 5.65 (d, J=6.6Hz, 1H), 5.03 (d, J=11.4Hz, 1H), 4.89 (br.s, 2H), 4.76 (d, J=12.0Hz, 1H), 4.57 (br.s, 2H), 4.41 (d, J=12.3Hz, 1H), and 4.02-4.14 (m, 2H), 3.35-3.86 (m, 7H), 2.81 (q, J=6.3Hz, 2H), 1.41-1.53 (m, 2H):
13CNMR (75MHz, DMSO-d
6) δ: 167.64,167.43,155.87,138.59,138.30,137.17,134.59,130.79,128.29,128.22,127.77,127.71,127.38,127.35,127.10,123.24,97.64,78.64,75.68,73.48,72.27,71.58,69.13,66.40,65.04,55.24,36.98,29.42; FAB-MS (M+H
+) 681. ultimate analyses (%): C
39H
40O
9N
2Calculated value: C:68.81, H:5.92, N:4.12. measured value: C:68.80, H:6.11, N:3.76.
(3) trisaccharide 2 is synthetic
Add 4 MS (1g) in the 50ml reaction flask, (815mg, 1.254mmol), (500mg, 1.045mmol), dry CH is injected in nitrogen protection to compound 10 to compound 9
2Cl
2(30ml) stir 0.5h, add under the frozen water condition NIS (660mg, 1.254mmol), TfOH (0.21ml, the diethyl ether solution of 0.5M, 0.105mmol), TLC shows that compound 10 primitive reactions are intact and generate a new point behind the reaction 0.5h, add again compound 13 (1.2g, 1.567mmol), NIS (660mg, 1.254mmol), TfOH (0.21ml, 0.5M diethyl ether solution, 0.105mmol), TLC detects and shows that the new point that previous step generates disappears substantially, adds triethylamine (5ml) and CH behind the reaction 3h
2Cl
2(30ml) dilution, diatomite filtration removes 4 MS, and filtrate is used saturated NaHCO successively
3With the NaCl washing, anhydrous sodium sulfate drying filters, and concentrates, and resistates uses column chromatography [eluent sherwood oil: acetone (v/v)=4: 1] and gets yellow oil 814mg, yield 55%.
1HNMR (500MHz, CDCl
3) δ: 8.00 (d, J=7.5Hz, 2H), 7.62 (m, 2H), 7.51 (t, J=7.5Hz, 1H), 7.10-7.38 (m, 39H), 6.97 (dd, J=2.0,7.5Hz, 2H), 6.77 (m, 3H), 5.64 (dd, J=8.5,10.0Hz, 1H), 5.31 (s, 1H), 4.96-5.06 (m, 6H), 4.79 (d, J=11.5Hz, 1H), 4.72 (d, J=8.5Hz, 1H), 4.50-4.63 (m, 5H), 4.44 (d, J=12.0Hz, 1H), 4.21-4.38 (m, 7H), 4.04-4.12 (m, 4H), 3.97 (dd, J=3.5,10Hz, 1H), 3.85 (m, 2H), 3.81 (dd, J=3.5,10.0Hz, 1H), 3.67-3.72 (m, 3H), and 3.51-3.55 (m, 2H), 3.38-3.41 (m, 2H), 3.27 (dd, J=7.0,9.0Hz, 1H), 3.15-3.18 (m, 1H), and 2.98-3.02 (m, 1H), 1.65-1.74 (m, 2H); TOF-MS (M+NH
4 +) 1574. ultimate analyses (%) C
93H
02O
20N
2Calculated value: C:71.71, H:5.95, N:1.80. measured value: C:71.49, H:5.89, N:1.55.
(4) deprotection of trisaccharide 2
In the 50ml reaction flask, add trisaccharide 2 (50mg), the alcoholic solution of methylamine (10ml), in 60 ℃ of reflux 10h, stopped reaction, reaction solution concentrates evaporate to dryness.Residue mixes stirring 8h, reconcentration evaporate to dryness with 5ml pyridine and 5ml acetic anhydride.The gained residue is dissolved in the methyl alcohol (15ml), adds sodium methylate (0.1ml, 30% methanol solution), and stirring at room 8h adds strongly acidic cation-exchange and is neutralized to neutrality, and behind the elimination resin, filtrate concentrates evaporate to dryness.Again debris is dissolved in 5ml HOAc: H
2O: THF=4: in 2: 1 the solvent, add 10%Pd/C (12mg), in the High Purity Hydrogen producer, carry out hydrogenation, after having reacted, filter out Pd/C, fully wash with methyl alcohol.Use C-18 reverse phase silica gel column purification at last, get the pure product of compound 2a, productive rate 72%.
The synthesis step of embodiment 3, pentasaccharides 3:
(1) compound 14 is synthetic
Add 4 MS (200mg) in the 25ml eggplant-shape bottle, (44.6mg, 0.069mmol), (12mg 0.063mmol), injects dry methylene chloride (2ml), N to BSP to compound 9
20.5h is stirred in protection, is cooled to subzero 70 ℃, injects Tf
2O (11.9 μ l, 19.46mg, 0.069mmol), behind the reaction 10min, with dry methylene chloride 2ml dissolved compound 10 (30mg, 0.063mmol) and add in the reaction flask, slowly rise to room temperature then, TLC detects and shows that raw material reaction is intact behind the 2h, adds triethylamine 2ml and CH
2Cl
2(10ml) dilution, diatomite filtration removes 4 MS, and filtrate is used saturated NaHCO successively
3With the NaCl washing, anhydrous sodium sulfate drying filters, and concentrates, and resistates uses column chromatography [eluent sherwood oil: ethyl acetate (V/V)=3: 1] and gets faint yellow oily thing 56mg, yield 90%.
1HNMR(500MHz，CDCl
3)δ：7.96(d，J＝8.0Hz，2H)，7.41-7.45(m，3H)，7.34(d，J＝7.5Hz，2H)，7.02-7.27(m，23H)，6.89((d，J＝8.0Hz，2H)，6.97(d，J＝8.0Hz，2H)，5.49(t，J＝9.5Hz，1H)，5.32(s，1H)，4.98(d，J＝3.0Hz，1H)，4.70(d，J＝11.8Hz，1H)，4.65(d，J＝9.5Hz，1H)，4.55(d，J＝12.0Hz，1H)，4.49(d，J＝11.5Hz，1H)，4.39(d，J＝11.5Hz，1H)，4.35(d，J＝12.0Hz，1H)，4.24-4.31(m，4H)，4.18(d，J＝12.0Hz，1H)，3.84-3.94(m，3H)，3.74(t，J＝6.0Hz，1H)，3.55(d，J＝10.0Hz，1H)，3.34(d，J＝13.0Hz，2H)，3.16(m，2H)，2.26(s，3H).
13CNMR(125MHz，CDCl
3)δ：164.65，138.51，134.20，132.96，129.83，129.47，128.93，128.32，128.22，128.18，128.11，128.03，127.82，127.62，127.48，127.42，127.34，127.25，126.57，101.06，94.60，85.41，78.58，75.77，75.45，74.91，74.58，74.25，73.12，72.20，71.76，69.90，69.82，69.35，68.97，68.63，21.26.TOF-MS(M+NH
4 +)1018。
(2) compound 16 is synthetic
(32.4g, 0.1mol), (1.6mol), (16.6g 0.2mol), is heated to 120 ℃ of stirring 3h that reflux to sodium-acetate to the anhydrous acetic acid acid anhydride, removes diacetyl oxide under reduced pressure and gets the deep yellow syrup, adds 200ml CH for 180ml, 163.2g to add lactose in the 500ml round-bottomed flask
2Cl
2Dissolving is with the saturated NaHCO about 150ml
3Solution washing 2-3 time is used saturated NaCl solution (100ml) washing, behind the anhydrous sodium sulfate drying again to neutral, the filtration drying agent concentrates, gained solid petroleum ether-ethyl acetate (V sherwood oil: V ethyl acetate=3: 2) recrystallization, get white solid 57.95g, productive rate: 85.5%.Reference
[82]Method.
(3) compound 17 is synthetic
(200mg is 0.3mmol) with compound H O (CH for compound 16
2)
3(63mg 0.35mmol) in the 50ml eggplant-shape bottle, adds the dry CH of 15ml to NHCbz
2Cl
2BF is injected in dissolving
3.OEt
2(1.01ml, 127.7mg 0.90mmol), stir 8h under the room temperature, and stopped reaction adds 50ml CH
2Cl
2Saturated NaHCO is used in dilution successively
3With the NaCl washing, anhydrous sodium sulfate drying filters, and concentrates, and gets yellow oil, and column chromatography for separation [eluent sherwood oil: ethyl acetate (V/V)=1: 1] gets yellow syrup 98.4mg, yield: 43%.
1HNMR(300MHz，CDCl
3)6：7.24-7.32(m，5H)，5.31(d，J＝2.7Hz，1H)，5.16(t，J＝9.6Hz，1H)，5.05-5.11(m，3H)，4.93(dd，J＝3.6，10.5Hz，1H)，4.85(dd，J＝7.8，9.6Hz，1H)，4.42-4.51(m，3H)，3.97-4.13(m，4H)，3.79-3.86(m，2H)，3.75(t，J＝9.6Hz，1H)，3.52-3.59(m，2H)，3.14-3.27(m，2H)，2.11(s，3H)，2.05(s，3H)，2.02(s，3H)，2.01(s，3H)，1.98(s，3H)，1.93(s，3H)，1.89(s，3H)，1.75(m，2H)；
13CNMR(75MHz，CDCl
3)δ：170.78，170.70，170.50，170.41，170.09，169.43，156.80，137.05，128.86，128.46，128.42，101.45，100.78，76.60，73.11，73.08，71.96，71.33，71.06，69.49，67.88，66.97，62.22，61.16，60.75，38.58，29.85，21.15，20.99，20.86；FAB-MS(M+H
+)828。
(4) compound 18 is synthetic
Compound 17 (107.5mg, 0.13mmol) in the 50ml reaction flask, add the dissolving of 20ml anhydrous methanol, inject NaOMe (10 μ l, 30% methanol solution, 0.0026mmol), stirring at room 5h, stopped reaction adds strongly acidic cation-exchange and is neutralized to neutrality, behind the elimination resin, concentrated evaporate to dryness gets yellow oil.In reaction flask, add Bu again
2(58mg 0.023mmol), injects anhydrous methanol 20ml, N to SnO
2Protection, reflux stirs 16h, is cooled to room temperature, and the evaporated under reduced pressure solvent adds 4 MS in resistates, tetrabutyl iodate amine (2.2mg 0.006mmol), injects the 20ml dry benzene, and allyl bromide 98 (18 μ l, 25.16mg, 0.208mmol), N
2Protection, reflux stirs 5h, is cooled to room temperature, and diatomite filtration removes 4 MS, and concentrated filtrate gets yellow oil.Repeatedly in reaction flask, add Bu
2(58mg 0.023mmol), injects anhydrous methanol 20ml, N to SnO
2Protection, reflux stirs 16h, is cooled to room temperature, and the decompressing and extracting solvent adds 4 MS in resistates, tetrabutyl iodate amine (2.2mg 0.006mmol), injects the 20ml dry benzene, and allyl bromide 98 (18 μ l, 25.16mg, 0.208mmol), N
2Protection, reflux stirs 5h, is cooled to room temperature, and diatomite filtration removes 4 MS, and concentrated filtrate gets yellow oil, drops into the next step after preliminary column chromatography for separation [eluent methyl alcohol: ethyl acetate (V/V)=1: 15].
Top gained compound is added in the 50ml eggplant-shape bottle, inject DMF (4ml) dissolving, be cooled to 0 ℃, add NaH (39mg, 1.56mmol), inject BnBr (0.14ml, 200.1mg, 1.17mmol), stir 5h, stopped reaction is poured compound in the frozen water into, use ethyl acetate (3 * 10ml) extractions then, the ethyl acetate layer anhydrous sodium sulfate drying filters, and concentrates, resistates gets yellow syrup 0.111g, yield: 70% through column chromatography for separation [eluent sherwood oil: ethyl acetate (V/V)=3: 1].
1HNMR(500MHz，CDCl
3)δ：7.12-7.34(m，40H)，5.92(m，1H)，5.32(dd，J＝1.5，17.0Hz，1H)，5.15-5.18(m，3H)，4.99(d，J＝11.0Hz，1H)，4.95(d，J＝11.5Hz，1H)，4.66-4.81(m，5H)，4.14-4.55(m，11H)，3.91(t，J＝10.0Hz，2H)，3.86(d，J＝2.5Hz，1H)，3.76(m，1H)，3.68(dd，J＝7.5，8.6Hz，2H)，3.53(t，J＝10Hz 2H)，3.29-3.35(m，8H)，1.85(m，2H)；
13CNMR(75MHz，CDCl
3)δ：162.64，139.10，139.09，138.86，138.62，138.31，138.07，137.88，134.97，128.49，128.43，128.34，128.23，128.19，128.12，128.01，127.93，127.87，127.82，127.71，127.65，127.50，127.46，127.41，127.39，127.29，127.03，116.38，103.46，102.72，82.91，82.34，81.71，79.86，77.20，76.58，75.32，75.21，75.08，74.91，74.59，73.48，73.38，73.01，72.92，71.46，68.28，68.08，67.15，50.77，36.59，31.55；MALDI-TOF-MS(M+Na
++H
+)1227，(M+K
++H
+)1243。
(5) compound 19 is synthetic
Get compound 18 (21mg, 0.017mmol) in the 25ml eggplant-shape bottle, N
2The 1.5ml anhydrous methanol is injected in protection, adds PdCl
2(1.1mg, 0.0068mmol), stirring at room 4h, reaction finishes, and adds methyl alcohol 5ml dilution, and diatomite filtration removes PdCl
2, concentrated filtrate, resistates gets buff syrup 19.8mg, productive rate: 97.5% through column chromatography for separation [eluent (v/v) sherwood oil: ethyl acetate=1: 2].
1HNMR(500MHz，CDCl
3)δ：7.14-7.34(m，40H)，5.15(br.s，2H)，5.00(d，J＝10.5Hz，1H)，4.25-4.81(m，16H)，3.95(t，J＝9.5Hz，1H)，3.86-3.92(m，1H)，3.83(br.s，1H)，3.66-3.79(m，2H)，3.26-3.56(m，10H)，2.18(d，J＝3.5Hz，1H)，1.85(m，2H).
13CNMR(75MHz，CDCl
3)δ：157.87，138.97，138.64，138.52，138.35，138.07，137.93，137.79，136.65，128.91，128.45，128.37，128.29，128.20，128.04，127.92，127.81，127.77，127.67，127.62，127.53，127.48，127.10，103.43，102.56，82.72，81.62，80.52，75.83，75.28，74.98，74.87，74.02，73.27，73.11，73.04，68.14，67.86，67.11，50.68，44.67，43.65，28.59；MALDI-TOF-MS(M+Na
++H
+)1187，(M+K
++H
+)1203。
(6) compound 20 is synthetic
(74mg, 0.18mmol), 3 MS (2.5g) inject dry THF (10ml), N to add compound 11 in reaction flask
2Protection, stirring at room 0.5h adds NaCNBH
3(0.11g 1.625mmol), injects HCl-Et
2(2.6ml, the diethyl ether solution of 1M 2.5mmol), have bubble to emit to O, and the 10min afterreaction is intact, add 10ml methylene dichloride dilute reaction solution, and diatomite filtration removes 3 MS, and filtrate is used saturated NaHCO successively
3With the NaCl washing, anhydrous sodium sulfate drying filters, and concentrates, and gets yellow oil, and column chromatography for separation [eluent sherwood oil: ethyl acetate (V/V)=3: 1] gets yellow syrup 43mg, yield: 58%.
1HNMR(300MHz，CD
3COCD
3-d
6)δ：7.69-7.84(m，4H)，7.27-7.40(m，7H)，6.88-7.01(m，7H)，5.56(d，J＝10.2Hz，1H)，4.83(d，J＝12.0Hz，1H)，4.51-4.64(m，3H)，4.28(dd，J＝7.8，10.2Hz，1H)，4.16(t，J＝10.2Hz，1H)，3.95(d，J＝9.3Hz，1H)，3.74-3.82(m，2H)，3.32(br.s，2H)，2.22(s，3H)。
(7) pentasaccharides 3 is synthetic
Add 4 MS (200mg) in the 25ml eggplant-shape bottle, (30mg, 0.03mmol), (2.9mg 0.015mmol), injects dry methylene chloride (2ml), N to BSP to compound 14
20.5h is stirred in protection, is cooled to subzero 70 ℃, injects Tf
2(0.018mmol), behind the reaction 10min, (21.5mg 0.036mmol), slowly rises to room temperature reaction 3h to O then, and TLC detection compound 14 disappears substantially to add compound 20 for 3.1 μ l, 5.6mg.Be cooled to-70 ℃ again, and adding BSP (2.9mg, 0.015mmol), Tf
2O (3.1 μ l, 5.6mg, 0.018mmol), behind the reaction 10min, with dry methylene chloride 2ml dissolved compound 19 (45mg, 0.039mmol) and add in the reaction flask, slowly rise to room temperature then, TLC detects and shows that the new point that previous step generates disappears substantially, adds triethylamine 2ml and CH behind the 3h
2Cl
2(10ml) dilution, diatomite filtration removes 4 MS, and filtrate is used saturated NaHCO successively
3With the NaCl washing, anhydrous sodium sulfate drying filters, and concentrates, and resistates gets faint yellow oily thing 31.4mg, yield 42% through column chromatography for separation [eluent sherwood oil: ethyl acetate (V/V)=2: 1].
1HNMR(500MHz，DMSO-d
6)δ：7.97(d，J＝7.5Hz，2H)，7.63-7.73(m，6H)，7.44(t，J＝7.5Hz，2H)，7.37-7.02(m，67H)，6.86(d，J＝7.5Hz，3H)，6.74(t，J＝7.5Hz，4H)，5.55(s，1H)，5.40(dd，J＝8.0，10.0Hz，1H)，5.32(d，J＝3.0Hz，1H)，5.28(d，J＝8.0Hz，1H)，5.05(s，2H)，4.90(d，J＝11.5Hz，1H)，4.87(d，J＝8.0Hz，1H)，4.75(d，J＝11.0Hz，1H)，3.92-4.65(m，36H)，33.76-3.80(m，3H)，3.18-3.76(m，16H)，2.95-3.14(m，2H)，1.66-1.75(m，2H)；
13CNMR(125MHz，DMSO-d
6)δ：167.44，164.52，155.80，139.14，138.86，138.58，138.34，138.27，138.03，137.98，137.87，136.89，134.37，133.64，131.53，130.50，129.38，128.93，128.76，128.65，128.39，128.30，128.17，128.10，127.99，127.88，127.82，127.72，127.61，127.54，127.40，127.35，127.21，127.16，127.02，126.91，126.70，126.29，126.17，123.06，102.25，101.23，100.04，99.99，99.01，93.34，81.84，80.97，78.06，77.66，77.41，76.85，76.41，75.14，74.44，74.19，74.13，74.05，73.66，73.56，73.40，73.31，72.53，72.47，72.34，71.88，71.22，70.81，68.94，68.38，68.15，68.04，67.90，67.40，66.28，66.10，65.03，55.80，49.95，48.60，44.48，43.61，30.00；MALDI-TOF-MS(M+Na
++H
+)2534，(M+K
++H
+)2550。
(8) deprotection of pentasaccharides 3
The deprotection of pentasaccharides 3 is identical with the deprotection operation steps of trisaccharide 2, gets compound 3a, deprotection total recovery 71%.
Embodiment 4 preparation of compositions
With the compound 20mg of general formula I of the present invention, II or III and 2ml injection physiological saline routinely the injection formulations method be prepared into injection.
The biological activity test result
With the anti-α of the people of purifying-Gal antibody (male sex, AB blood group) as antibody, with the glutinous a-Gal antigen that connects albumen as natural origin of mouse layer, measure synthetic antigen to bonded restraining effect between natural antigen and antibody with the ELISA method, PRELIMINARY RESULTS shows that they have stronger restraining effect to combining between antigen and antibody.Determination data is as follows:
The synthetic oligosaccharides is to anti-a-Gal antibody of people and the glutinous even protein bound inhibiting preliminary experiment result of mouse layer
| Compound | IC 50(μ M) | ||
| IgG | IgA | IgM | |
| 1a 2a 3a | 15 35 2.5 | 11 27 1.3 | 50 135 8.2 |
Claims (3)
1. formula 1a compound
The preparation method, comprising:
(A) allow compound 4, promptly 1,2,3,4,6-penta-acetyl glucose
In the presence of etherate of trifluoroboron and inert solvent with HO (CH
2)
3The NHCbz reaction to introduce side chain, obtains compound 5:
(B) take off the protection of acetyl and benzal base then, obtain compound 6:
(C) benzylization then obtains compound 7:
(D) selective opening then obtains compound 8:
(E) compound 8 and following compound 9 and 10 couplings then,
Obtain compound 1,
Optional then deprotection: successively use 1) H NaOMe/MeOH and 2)
2/ Pd-C/H
2O/THF/CH
3COOH handles deprotection, obtains the compound 1a of following formula:
2. formula 2a compound
The preparation method, comprising:
(A) compound 11
With HO (CH
2)
3The NHCbz reaction to introduce side chain, obtains compound 12:
(B) selective opening then obtains compound 13:
(C) compound 9 and 10 couplings described in compound 13 and the claim 1 then obtain compound 2
Optional then deprotection: successively use 1) alcoholic solution of methylamine is under the temperature of room temperature-60 ℃, and 2) Ac
2O/Pyr, 3) NaOMe/MeOH and 4) H
2/ Pd-C/THF/H
2O/CH
3COOH handles deprotection, obtains following formula: compound 2a:
3. formula 3a compound
The preparation method, comprising:
(A), obtain compound 14 with compound described in the claim 19 and 10 couplings:
(B) with lactose 15:
Acetylize obtains compound 16:
Then with HO (CH
2)
3The NHCbz reaction to introduce side chain, obtains compound 17:
Deacetylated then, introduce allyl group, benzylization obtains compound 18:
Take off allyl group then, obtain compound 19:
(C) compound 14, compound 19 and following compound 20 couplings,
Obtain compound 3,
Optional again deprotection: successively use 1) alcoholic solution of methylamine is under the temperature of room temperature-60 ℃,
2) Ac
2O/Pyr, 3) NaOMe/MeOH and 4) H
2/ Pd-C handles deprotection, obtains following formula: compound 3a:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031560989A CN100365007C (en) | 2003-09-01 | 2003-09-01 | New type trisaccharide and penta saccharid oligo saccharide antigen, their synthesis method and application in preparation of medicine for inhibiting exclusion reaction |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031560989A CN100365007C (en) | 2003-09-01 | 2003-09-01 | New type trisaccharide and penta saccharid oligo saccharide antigen, their synthesis method and application in preparation of medicine for inhibiting exclusion reaction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1590394A CN1590394A (en) | 2005-03-09 |
| CN100365007C true CN100365007C (en) | 2008-01-30 |
Family
ID=34598308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031560989A Expired - Lifetime CN100365007C (en) | 2003-09-01 | 2003-09-01 | New type trisaccharide and penta saccharid oligo saccharide antigen, their synthesis method and application in preparation of medicine for inhibiting exclusion reaction |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100365007C (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103073495B (en) * | 2013-02-06 | 2015-08-05 | 苏州立新制药有限公司 | The preparation method that a kind of ent-3-methoxyl group is muttered |
| CN103709212B (en) * | 2013-12-12 | 2016-08-17 | 济南尚博生物科技有限公司 | A kind of technique preparing 2,3,4,6-tetra--oxygen-benzyl-D-galactopyranose |
| CN103694287B (en) * | 2013-12-12 | 2016-05-18 | 济南尚博生物科技有限公司 | The technique of preparation 2,3,4,6-tetra--oxygen-benzyl-D-galactopyranose |
| CN103694290B (en) * | 2013-12-12 | 2016-08-17 | 济南尚博生物科技有限公司 | The preparation method of 2,3,4,6-tetra--oxygen-benzyl-D-galactopyranose |
| CN103694289B (en) * | 2013-12-12 | 2016-05-18 | 济南尚博生物科技有限公司 | A kind of preparation method of 2,3,4,6-, tetra--oxygen-benzyl-D-galactopyranose |
| CN103665064B (en) * | 2013-12-12 | 2016-04-27 | 济南尚博生物科技有限公司 | One prepares the method for 2,3,4,6-, tetra--oxygen-benzyl-D-galactopyranose |
| CN103694288B (en) * | 2013-12-12 | 2016-05-18 | 济南尚博生物科技有限公司 | The method of preparation 2,3,4,6-tetra--oxygen-benzyl-D-galactopyranose |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1252807A (en) * | 1997-04-18 | 2000-05-10 | 诺瓦提斯公司 | Neoglycoproteins |
-
2003
- 2003-09-01 CN CNB031560989A patent/CN100365007C/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1252807A (en) * | 1997-04-18 | 2000-05-10 | 诺瓦提斯公司 | Neoglycoproteins |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1590394A (en) | 2005-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2635413T3 (en) | An efficient and scalable process for the manufacture of fondaparinux sodium | |
| CN102459294A (en) | Synthesis of 2' -O-fucosyllactose | |
| CA3140411C (en) | Saponin conjugate and vaccine or pharmaceutical composition comprising the same | |
| JP2016530212A (en) | Protein- and peptide-free synthetic vaccine against Streptococcus pneumoniae type 3 | |
| US20120264702A1 (en) | Synthesis And Use Of Glycoside Derivatives of Propofol | |
| WO2012142141A1 (en) | Synthesis and use of glycoside pro-drug analogs | |
| CN100365007C (en) | New type trisaccharide and penta saccharid oligo saccharide antigen, their synthesis method and application in preparation of medicine for inhibiting exclusion reaction | |
| JP3771445B2 (en) | Anticancer agent containing sulfopyranosyl acylglycerol derivative | |
| JP3851461B2 (en) | Pyranoside and process for producing the same | |
| CN106432371A (en) | Beta-1,2-D-oligomeric mannoprotein conjugates and preparation method and application thereof | |
| WO1998031392A1 (en) | Nephrotropic drugs | |
| ES2235362T3 (en) | SUBSTITUTED TETRAHYDROPIRANE DERIVATIVES, AS WELL AS PROCEDURES FOR PREPARATION | |
| CN100338084C (en) | Synthetic method for pentose antigen for inhibiting heterogenic organ transplant immune rejection reaction | |
| WO2008062842A1 (en) | Sodium salt of disaccharide compound, method for producing the same, and use of the same | |
| WO2001051499A1 (en) | METHODS FOR SYNTHESIS OF α-D-GAL (1→3) GAL-CONTAINING OLIGOSACCHARIDES | |
| AU2007344284B8 (en) | Use of modified oligo-beta-(1,3)-glucans for treating diseases of the immune system, oligo- beta - (1,3)-glucan-(1,3)- mannose, oligo- beta -(1,3)-glucan-(1,3)- mannitol and derivatives thereof, methods for preparing them and medicaments containing them | |
| Buskas et al. | Synthesis of oligosaccharides designed to form micelles, corresponding to structures found in ovarian cyst fluid | |
| US7605255B2 (en) | Non-animal based lactose | |
| JPH0680686A (en) | Acidic functional group-bearing lipid derivative and fine carrier particle coated therewith | |
| KR101589633B1 (en) | Novel Glycoceramides and Process for Preparing Thereof | |
| JP5126706B2 (en) | Method for synthesizing a library of compounds having two or more hydroxyl groups | |
| KR101571765B1 (en) | Novel Pulsatilla saponin D derivatives, preparation and anticancer use therof | |
| JP4224429B2 (en) | Sulfoquinovosyl acylglycerol | |
| JPH0680702A (en) | Acidic sugar derivative | |
| WO2003106473A1 (en) | 1-carboxymethyl analogues of glucosyl lipid a |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20080130 |